

### CROSS COUNTRY HEALTHCARE ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS

BOCA RATON, Fla., May 5, 2021--Cross Country Healthcare, Inc. (the "Company") (Nasdaq: CCRN) today announced financial results for its first quarter ended March 31, 2021.

#### SELECTED FINANCIAL INFORMATION:

			Variance	Τ	Variance			
	1		Q1 2021 vs		Q1 2021 vs			
Dollars are in thousands, except per share amounts	上	Q1 2021	Q1 2020	┖	Q4 2020			
Revenue	\$	329,241	57 %	L	53 %			
Gross profit margin*		21.7 %	(190) bps		(350) bps			
Net income attributable to common shareholders	\$	19,448	1,031 %	L	322 %			
Diluted EPS	\$	0.53	\$ 0.59	\$	0.40			
Adjusted EBITDA*	\$	26,733	480 %		132 %			
Adjusted EBITDA margin*		8.1 %	590 bps		280 bps			
Adjusted EPS*	\$	0.58	\$ 0.59	\$	0.39			
Cash flows used in operations	\$	(24,927)	(245) %		(1,392) %			

<sup>\*</sup> Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.

"We entered the year on a very positive trajectory, with solid execution, higher productivity, and exceptional performance," said Kevin Clark, Co-founder and Chief Executive Officer for Cross Country Healthcare. He continued, "This was the single largest revenue quarter in our Company's history and was fueled by our passionate, tireless efforts to deliver the critical professionals needed across the country."

First quarter consolidated revenue was \$329.2 million, an increase of 57% year-over-year and 53% sequentially. Consolidated gross profit margin was 21.7%, down 190 basis points year-over-year and 350 basis points sequentially. Net income attributable to common shareholders was \$19.4 million compared to a net loss of \$2.1 million in the prior year and net income of \$4.6 million in the prior quarter. Diluted earnings per share (EPS) was \$0.53 per share compared to a loss of \$0.06 per share in the prior year and income of \$0.13 per share in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was \$26.7 million or 8.1% of revenue, as compared with \$4.6 million or 2.2% of revenue in the prior year, and \$11.5 million or 5.3% of revenue in the prior quarter. Adjusted EPS was \$0.58 compared to a loss of \$0.01 in the prior year and income of \$0.19 in the prior quarter.

#### **Quarterly Business Segment Highlights**

In the first quarter of 2021, the Company modified its reportable segments to the following two reportable segments – Nurse and Allied Staffing and Physician Staffing. Previously reported Search segment results have been reclassified to Nurse and Allied Staffing. See accompanying tables below.

#### Nurse and Allied Staffing

Revenue was \$313.0 million, an increase of 63% year-over-year and 57% sequentially. Contribution income was \$37.4 million, an increase compared to \$13.8 million in the prior year and \$22.8 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis were 6,614 as compared with 7,145 in the prior year and 5,798 in the prior quarter. Revenue per FTE per day was \$522 compared to \$290 in the prior year and \$368 in the prior quarter. As a result of the rise in demand and a tight labor market, our average travel bill rates increased due to the increases in pay rates required to attract healthcare professionals. Throughout the coronavirus pandemic (COVID-19), we have worked with our clients to adjust bill rates, both increasing and decreasing rates as necessary, to provide critical healthcare professionals.

#### Physician Staffing

Revenue was \$16.2 million, a decrease of 11% year-over-year and 1% sequentially. Contribution income was \$1.4 million, an increase compared to \$0.6 million in the prior year and \$0.9 million in the prior quarter. Total days filled were 9,469 as compared with 10,199 in the prior year and 9,911 in the prior quarter. Revenue per day filled was \$1,714 as compared with \$1,783 in the prior year and \$1,658 in the prior quarter.

#### **Cash Flow and Balance Sheet Highlights**

Cash flow used in operations for the quarter was \$24.9 million compared to cash flow provided by operations of \$17.2 million in the prior year and \$1.9 million in the prior quarter, primarily due to strong sequential revenue growth which resulted in a \$76.6 million increase in receivables since the start of the year. Days' sales outstanding was 56 days as of March 31, 2021, flat year-over-year and down 2 days sequentially.

At March 31, 2021, the Company had \$13.5 million in cash and cash equivalents, \$96.0 million of borrowings drawn under its asset-based loan facility (ABL), and \$18.5 million of letters of credit outstanding. Availability under the ABL is subject to a borrowing base, which was \$150.0 million as of March 31, 2021, with \$35.5 million available for borrowing as of March 31, 2021.

#### **Outlook for Second Quarter 2021**

The guidance below applies to management's expectations for the second guarter of 2021.

		Year-over-Year	Sequential
	Q2 2021 Range	Change	Change
Revenue	\$300 million - \$310 million	38% - 43%	(9)% - (6)%
Gross Profit Margin*	22.0% - 22.5%	(140) bps - (90) bps	30 bps - 80 bps
Adjusted EBITDA*	\$19.0 million - \$21.0 million	64% - 81%	(29)% - (21)%
Adjusted EPS*	\$0.37 - \$0.42	\$0.21 - \$0.26	\$(0.21) - \$(0.16)

<sup>\*</sup> Refer to discussion of non-GAAP financial measures below.

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future share repurchases. We expect COVID-19 will continue to impact our business throughout the second quarter, with average bill rates remaining higher than the prior year though declining sequentially for certain assignments, as well as lower demand for certain services such as locum tenens, education, and search. See accompanying non-GAAP financial measures and tables below.

#### INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Wednesday, May 5, 2021, at 5:00 P.M. Eastern Time to discuss its first quarter 2021 financial results. This call will be webcast live and can be accessed at the Company's website at ir.crosscountryhealthcare.com or by dialing 888-566-1099 from anywhere in the U.S. or by dialing 773-799-3716 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from May 5th through May 19th at the Company's website and a replay of the conference call will be available by telephone by calling 800-510-0118 from anywhere in the U.S. or 203-369-3808 from non-U.S. locations - Passcode: 2021.

#### ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare, Inc. (CCH) is a leader in providing total talent management including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. Leveraging our 35 years of industry expertise and insight, CCH solves complex labor-related challenges for customers while providing high-quality outcomes and exceptional patient care. As a multi-year Best of Staffing® Award winner, CCH is committed to an exceptionally high level of service to both our clients and our healthcare professionals. CCH was the first publicly traded staffing firm to obtain The Joint Commission Certification, which it still holds with a Letter of Distinction. In February 2021, CCH earned Energage's inaugural 2021 Top Workplaces USA award. CCH has a longstanding history of investing in its diversity, equality, and inclusion strategic initiatives as a key component of the organization's overall corporate social responsibility program which is closely aligned with its core values to create a better future for its people, communities, the planet, and its shareholders.

Copies of this and other news releases as well as additional information about the Company can be obtained online at ir.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

#### **NON-GAAP FINANCIAL MEASURES**

This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

#### FORWARD LOOKING STATEMENTS

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act, and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "suggests", "appears", "seeks", "will", "could", and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients' ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in

our other filings with the SEC. You should consult any further disclosures the Company makes on related subjects in its filings with the SEC.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors' likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, and/or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to "we", "us", "our", or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its subsidiaries.

# Cross Country Healthcare, Inc. Consolidated Statements of Operations (Unaudited, amounts in thousands, except per share data)

	Three Months Ended					
	March 31,		M	larch 31,	Dec	cember 31,
		2021		2020		2020
Revenue from services	\$	329,241	\$	210,064	\$	215,606
Operating expenses:						
Direct operating expenses		257,776		160,461		161,214
Selling, general and administrative expenses		46,327		45,881		44,870
Bad debt expense		504		539		652
Depreciation and amortization		2,253		3,296		2,199
Acquisition and integration-related costs		_		77		_
Restructuring costs		1,238		564		842
Impairment charges		149				166
Total operating expenses		308,247		210,818		209,943
Income (loss) from operations		20,994		(754)		5,663
Other expenses (income):						
Interest expense		671		867		671
Other (income) expense, net		(37)		(31)		326
Income (loss) before income taxes		20,360		(1,590)		4,666
Income tax expense (benefit)		912		178		(156)
Consolidated net income (loss)		19,448		(1,768)		4,822
Less: Net income attributable to noncontrolling interest in subsidiary				321		210
Net income (loss) attributable to common shareholders	\$	19,448	\$	(2,089)	\$	4,612
Net income (loss) per share attributable to common shareholders - Basic	\$	0.54	\$	(0.06)	\$	0.13
Net income (loss) per share attributable to common shareholders - Diluted	\$	0.53	\$	(0.06)	\$	0.13
Weighted average common shares outstanding:						
Basic		36,181		35,873		36,177
Diluted		37,034		35,873		36,778

# Cross Country Healthcare, Inc. Reconciliation of Non-GAAP Financial Measures (Unaudited, amounts in thousands, except per share data)

May			Three Months Ended				
Adjusted EBITDA**         S 19,448         \$ 0,2089         \$ 4,612           Not mome (loss) attributable to common shareholders         \$ 19,448         \$ 0,708         671           Increst expense         671         867         671           Increst expenses (benefit)         912         173         (156)           Depreciation and amortization         2,253         3,296         2,196           Acquisition and integration-related costs*         -         77         -           Restructuring costs*         1238         564         842           Legal settlements and fees*         1375         -         600           Inspainment changes*         149         -         166           Oben inspainment changes*         1379         27         1,340           Oben income, et         (37)         (31)         (38)           Use on disposal of fixed asets         -         375         502         690           Oben income, et         (37)         321         210           Applicant Extraking system costs*         -         4,32         2,33           Not extracting system costs*         -         4,612         1,130           Applicated ESP*         -         7,7         - <th></th> <th>N</th> <th colspan="2">March 31,</th> <th>March 31,</th> <th colspan="2"></th>		N	March 31,		March 31,		
Net incented (sos) attributable to common shareholders         \$ 19,448         \$ (20,89)         \$ 4,612           Interest expenses         671         867         671           Income tax expense (benefit)         912         178         (1560)           Depreciation and amortization         2,233         3,206         2,199           Acquisition and integration-related costs*         —         77         —           Restructuring costs*         11,238         564         842           Legal settlements and foces*         375         —         600           Impairment charges*         140         —         360           Loss on disposal of fixed assets         —         —         361           Other income, net         373         927         1,349           Applicant tracking system costs*         375         920         600           Applicant tracking system costs*         375         920         600           Aguitated EBITDA*         \$ 22,733         \$ 24,612         \$ 21,000           Aguitated EBITDA margin*         \$ 19,448         \$ 0,205         \$ 3,75           Not income attributable to common shareholders         \$ 19,448         \$ 0,205         \$ 0,205           Not GAAP adjustments - proteix			2021		2020	2020	
Interest expense (benefit)		•			(* 000)		
Income tax expense (benefit)		\$		\$		\$	<i>'</i>
Depreciation and amortization	•						
Acquisition and integration-related costs <sup>16</sup> — Restructuring costs <sup>7</sup> 1,238         564         82           Legal settlements and foces <sup>6</sup> 375         — 600           Impairment charges <sup>7</sup> 149         — 600           Loss on disposal of fixed assets         — 7         — 63           Other income, net         (37)         (31)         (38)           Equity compensation         1,349         927         1,340           Applicant tracking system costs <sup>7</sup> 321         210           Not income attributable to noncontrolling interest in subsidiary <sup>8</sup> — 321         210           Adjusted EBITDA <sup>7</sup> 26,733         3,4612         31,500           Adjusted EPIS **         8         2,089         3,612           Non-GAAP adjustments pertax:         8         2,089         4,612           Non-GAAP adjustments pertax:         9         7,7         — 6           Non-GAAP adjustments pertax:         9         7,7         — 6           Non-GAAP adjustments pertax:         9         1,238         5,64         8,2           Non-GAAP adjustments pertax:         9         1,23         5,60         8,2           Restructuring costs <sup>2</sup> 1,23         5,0         <	• • •						` /
Restructuring costs**         1,238         564         842           Legal settlements and foes**         375         —         600           Impairment charges*         149         —         160           Loss on disposal of fixed assets         —         —         364           Other income, net         (37)         (31)         (38)           Equify compensation         1,349         927         1,340           Applicant tracking system costs*         375         502         690           Net income attributable to noncontrolling interest in subsidiary*         —         321         2,100           Adjusted EBITDA*         \$ 26,733         \$ 4612         \$ 11,500           Adjusted EPIS**         *         \$ 26,733         \$ 4612         \$ 11,500           Adjusted EPIS*         *         *         \$ 20         \$ 3,35           Adjusted EPIS**         *         *         \$ 20         \$			2,253				2,199
Legal settlements and feed			_				_
Impairment charges*         149         —         166           Loss on disposal of fixed asets         —         363           Other income, net         637         3(31)         388           Equity compensation         1,349         927         1,340           Applicant tracking system costs*         52         502         690           Net income attributable to noncontrolling interest in subsidiary*         —         321         210           Adjusted EBITDA*         \$26,733         \$4,612         \$11,500           Adjusted EBITDA margin*         8         \$2,6733         \$4,612         \$1,500           Adjusted EBITDA margin*         8         \$1,948         \$2,899         \$4,612           Numerator         8         \$1,948         \$2,089         \$4,612           Numerator         8         \$1,948         \$2,089         \$4,612           Non-GAAP adjustments - pretax:         —         7         —           Restructuring costs*         1,238         564         842           Legal settlements and fees*         1,238         564         842           Legal settlements and fees*         1,49         —         166           Rebranduing impatriments and accelerated amortization* <td>e e e e e e e e e e e e e e e e e e e</td> <td></td> <td>*</td> <td></td> <td>564</td> <td></td> <td></td>	e e e e e e e e e e e e e e e e e e e		*		564		
Coss on disposal of fixed assets					_		
Other income, net         (37)         (31)         (38)           Equity compensation         1,349         927         1,340           Applicant tracking system costs <sup>6</sup> 375         502         690           Net income attributable to noncontrolling interest in subsidiary <sup>8</sup> ————————————————————————————————————			149		_		
Equity compensation         1,349         927         1,340           Applicant tracking system costs <sup>2</sup> 690         690           Net income attributable to one controlling interest in subsidiary <sup>2</sup> 2         321         210           Adjusted EBITDA*         8.19**         2.20**         5.37**           Adjusted EBITDA margin*         8.19**         2.20**         5.37**           Adjusted EBITDA margin*         8.19**         2.20**         5.37**           Adjusted EBITDA margin*         8.19**         2.20**         5.30**           Adjusted EBITDA margin*         8.19**         \$ (2,089)         \$ 4,612           Water transported to Stripturated Expression and transport of the income (loss) attributable to common shareholders         8.19**         \$ (2,089)         \$ 4,612           Nor-Gazza adjustments and indegration-related costs <sup>5</sup> -         7.7         -         -         8.21**         8.21**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         8.24**         9.24**         9.24**         9.24**         9.24**         9.24**         9.24**         9.24**         9.24**         9.24** <t< td=""><td></td><td></td><td>_</td><td></td><td>_</td><td></td><td>364</td></t<>			_		_		364
Applicant tracking system costs f         375         502         60           Net income attributable to noncontrolling interest in subsidiary dijusted EBITDA*         321         210           Adjusted EBITDA anagin*         8.26,733         \$4,612         \$1,500           Adjusted EBITDA margin*         8.1%         \$2.2%         \$5.3%           Adjusted EPS*         8.1%         \$2.2%         \$5.3%           None Consecutions of the common shareholders         8.19,448         \$0.2089         \$4,612           None GAAP adjustments - pretax:         8.19,448         \$0.2089         \$4,612           None GAAP adjustments - pretax:         9.77         -         -           Restructuring costs*         1,238         564         842           Legal settlements and fices d         3375         -         600           Impairment charges (excluding rebranding impacts)*         149         -         166           Rebranding impairments and accelerated amortization*         375         502         600           Nonrecurring income tax adjustments         -         731         -           Tax impact of non-GAAP adjustments         3         35         50.2         800           Nonrecurring income tax adjustments         3         30.8	Other income, net		(37)		(31)		(38)
Net income attributable to noncontrolling interest in subsidiarys <sup>8</sup> — 321 (200)           Adjusted EBITDA <sup>8</sup> \$ 26,733 (200)         \$ 4,612 (200)         \$ 11,500           Adjusted EBITDA and pairs         8.1% (200)         \$ 3.3%         \$ 3.3%           Adjusted EBITDA but and pairs         \$ 19,448 (2008)         \$ 20,809 (2008)         \$ 4,612 (2008)			1,349		927		1,340
Adjusted EBITDA*         \$ 26,733         \$ 4,612         \$ 11,500           Adjusted EBITDA margin*         8.1 %         2.2 %         5.3 %           Adjusted EPS*         Series of Ser	Applicant tracking system costs <sup>f</sup>		375		502		690
Adjusted EBITDA margin³         8.1 %         2.2 %         5.3 %           Adjusted EPS.*         Valuation         Valuation <th< td=""><td>Net income attributable to noncontrolling interest in subsidiary<sup>g</sup></td><td></td><td></td><td></td><td>321</td><td></td><td>210</td></th<>	Net income attributable to noncontrolling interest in subsidiary <sup>g</sup>				321		210
Adjusted EPS.*           Numerator:         Numerator:           Net income (loss) attributable to common shareholders         \$ 19,448         \$ (2,089)         \$ 4,612           Non-GAAP adjustments - pretax:         To pretax:	Adjusted EBITDA <sup>a</sup>	\$	26,733	\$	4,612	\$	11,500
Numerators:         Net income (loss) attributable to common shareholders         \$ 19,448         \$ (2,089)         \$ 4,612           Non-GAAP adjustments - pretax:	Adjusted EBITDA margin <sup>a</sup>		8.1 %		2.2 %		5.3 %
Net income (loss) attributable to common shareholders         \$ 19,448         \$ (2,089)         \$ 4,612           Non-GAAP adjustments - pretax:         Acquisition and integration-related costs <sup>b</sup> − 77         − 2           Restructuring costs <sup>c</sup> 1,238         564         842           Legal settlements and fees <sup>d</sup> 375         − 600           Impairment charges (excluding rebranding impacts) <sup>c</sup> 149         − 731         − 600           Rebranding impairments and accelerated amortization <sup>c</sup> 375         502         609           Rebranding impairments and accelerated amortization <sup>c</sup> 375         502         609           Nonrecurring income tax adjustments         −         731         −           Nonrecurring income tax adjustments         −         70         (18)           Tax impact of non-GAAP adjustments         2         21,583         \$ 227         \$ 6,890           Denominator:         2         21,583         \$ 227         \$ 6,890           Denominator:         36,181         35,873         36,177           Dilutive impact of share-based payments of share-based, GAAP         36,181         35,873         36,178           Reconciliation:         Teconciliation:           Diluted	Adjusted EPS:h						
Non-GAAP adjustments - pretax:         —         77         —           Acquisition and integration-related costs <sup>b</sup> —         77         —           Restructuring costs <sup>c</sup> 1,238         564         842           Legal settlements and fees <sup>d</sup> 375         —         600           Impairment charges (excluding rebranding impacts) <sup>c</sup> 149         —         731         —           Rebranding impairments and accelerated amortization <sup>c</sup> —         731         —           Applicant tracking system costs <sup>c</sup> 375         502         690           Nonrecurring income tax adjustments         —         (18)         (18)           Tax impact of non-GAAP adjustments         —         (2)         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         —         —         \$ 6,890           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>d</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         \$ 9,03         \$ 0,00         \$ 0,78           Pill	Numerator:						
Acquisition and integration-related costs <sup>b</sup> —         77         —           Restructuring costs <sup>c</sup> 1,238         564         842           Legal settlements and fees <sup>d</sup> 375         —         600           Impairment charges (excluding rebranding impacts) <sup>c</sup> 149         —         166           Rebranding impairments and accelerated amortization <sup>c</sup> —         731         —           Applicant tracking system costs <sup>f</sup> 375         502         690           Nonrecurring income tax adjustments         —         —         (18)           Tax impact of non-GAAP adjustments         —         —         (18)           Tax impact of none (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         —         —         —         —           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>i</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         \$ 0,33         \$ 0,03         9,02           Reconciliation:         —         —         0         0         0           Non-GAAP adjustmen	Net income (loss) attributable to common shareholders	\$	19,448	\$	(2,089)	\$	4,612
Restructuring costs <sup>c</sup> 1,238         564         842           Legal settlements and fees <sup>d</sup> 375         —         600           Impairment charges (excluding rebranding impacts) <sup>c</sup> 149         —         166           Rebranding impairments and accelerated amortization <sup>c</sup> —         731         —           Applicant tracking system costs <sup>c</sup> 375         502         690           Nonrecurring income tax adjustments         —         —         (18)           Tax impact of non-GAAP adjustments         —         —         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         —         —         —         —         (18)           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>d</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         \$ 0,33         36,328         36,778           Reconciliation:         —         —         0.00         \$ 0.13           Non-GAAP adjustments - pretax:         —         0.03         0.02         0.02	Non-GAAP adjustments - pretax:						
Legal settlements and fees <sup>d</sup> 375         —         600           Impairment charges (excluding rebranding impacts) <sup>e</sup> 149         —         166           Rebranding impairments and accelerated amortization <sup>e</sup> —         731         —           Applicant tracking system costs <sup>f</sup> 375         502         690           Nonrecurring income tax adjustments         —         —         (18)           Tax impact of non-GAAP adjustments         (2)         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         —         853         455         601           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>i</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         \$ 0,53         \$ 0,06         \$ 0,13           Reconciliation:         —         —         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0<	Acquisition and integration-related costs <sup>b</sup>		_		77		_
Impairment charges (excluding rebranding impacts)	Restructuring costs <sup>c</sup>		1,238		564		842
Rebranding impairments and accelerated amortization <sup>c</sup> —         731         —           Applicant tracking system costs <sup>f</sup> 375         502         690           Nonrecurring income tax adjustments         —         —         —         (18)           Tax impact of non-GAAP adjustments         —         —         —         (2)         (12)         —         (2)         —         —         (2)         —         —         (3)         —         —         —         (3)         —         —         —         601         —         —         —         —         —         —         —         —         —         —         —	Legal settlements and fees <sup>d</sup>		375		_		600
Applicant tracking system costsf         375         502         690           Nonrecurring income tax adjustments         —         —         —         (18)           Tax impact of non-GAAP adjustments         (2)         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments in pact of share-based payments in pact of share-based payments in pact of share adjustment share - diluted, non-GAAP         37,034         36,328         36,778           Reconciliation:         —         0.53         \$ (0.06)         \$ 0.13           Non-GAAP adjustments - pretax:         Restructuring costs end of costs of the cost of			149		_		166
Nonrecurring income tax adjustments         —         —         —         (18)           Tax impact of non-GAAP adjustments         (2)         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         ***         ***         ***         36,181         35,873         36,177           Dilutive impact of share-based payments in plutted overage common shares - diluted, non-GAAP         37,034         36,328         36,778           Adjusted weighted average common shares - diluted, non-GAAP         \$ 0.53         \$ (0.06)         \$ 0.13           Reconciliation:         ***         ***         ***         0.02         0.02           Non-GAAP adjustments - pretax:         ***         ***         0.02         0.02           Restructuring costs exercituring costs exercituring costs exercity co			_		731		_
Tax impact of non-GAAP adjustments         (2)         (12)         (2)           Adjusted net income (loss) attributable to common shareholders - non-GAAP         \$ 21,583         \$ (227)         \$ 6,890           Denominator:         \$ 21,583         \$ (227)         \$ 6,890           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments in painter based payments in			375		502		690
Adjusted net income (loss) attributable to common shareholders - non-GAAP  Denominator:  Weighted average common shares - basic, GAAP Dilutive impact of share-based payments and accelerated amortization and place and payments and accelerated amortization and page	Nonrecurring income tax adjustments		_		_		(18)
Denominator:           Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>1</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         37,034         36,328         36,778           Reconciliation:         Diluted EPS, GAAP         \$ 0.53         \$ (0.06)         \$ 0.13           Non-GAAP adjustments - pretax:         Restructuring costs <sup>c</sup> 0.03         0.02         0.02           Legal settlements and fees <sup>d</sup> 0.01         —         0.02           Rebranding impairments and accelerated amortization <sup>c</sup> —         0.02         —           Applicant tracking system costs <sup>f</sup> 0.01         0.01         0.01         0.02	Tax impact of non-GAAP adjustments		(2)		(12)		(2)
Weighted average common shares - basic, GAAP         36,181         35,873         36,177           Dilutive impact of share-based payments <sup>1</sup> 853         455         601           Adjusted weighted average common shares - diluted, non-GAAP         37,034         36,328         36,778           Reconciliation:         Diluted EPS, GAAP         \$ 0.53         \$ (0.06)         \$ 0.13           Non-GAAP adjustments - pretax:         8         8         0.02         0.02           Restructuring costs <sup>2</sup> 0.03         0.02         0.02           Legal settlements and fees <sup>d</sup> 0.01         —         0.02           Rebranding impairments and accelerated amortization <sup>e</sup> —         0.02         —           Applicant tracking system costs <sup>f</sup> 0.01         0.01         0.02	Adjusted net income (loss) attributable to common shareholders - non-GAAP	\$	21,583	\$	(227)	\$	6,890
Dilutive impact of share-based payments and accelerated amortization Adjusted weighted average common shares - diluted, non-GAAP 37,034 36,328 36,778  Reconciliation:  Diluted EPS, GAAP \$ 0.53 \$ (0.06) \$ 0.13  Non-GAAP adjustments - pretax:  Restructuring costs 9 0.03 0.02 0.02  Legal settlements and fees 9 0.01 - 0.02  Rebranding impairments and accelerated amortization 9 0.01 0.02  Applicant tracking system costs 1 0.01 0.01 0.02	Denominator:						
Adjusted weighted average common shares - diluted, non-GAAP         37,034         36,328         36,778           Reconciliation:         Diluted EPS, GAAP         \$ 0.53         \$ (0.06)         \$ 0.13           Non-GAAP adjustments - pretax:         Restructuring costs <sup>c</sup> 0.03         0.02         0.02           Legal settlements and fees <sup>d</sup> 0.01         -         0.02           Rebranding impairments and accelerated amortization <sup>c</sup> -         0.02         -           Applicant tracking system costs <sup>f</sup> 0.01         0.01         0.01         0.02	Weighted average common shares - basic, GAAP		36,181		35,873		36,177
Reconciliation:  Diluted EPS, GAAP \$ 0.53 \$ (0.06) \$ 0.13  Non-GAAP adjustments - pretax:  Restructuring costs <sup>c</sup> 0.03 0.02 0.02  Legal settlements and fees <sup>d</sup> 0.01 — 0.02  Rebranding impairments and accelerated amortization <sup>c</sup> — 0.02 —  Applicant tracking system costs <sup>f</sup> 0.01 0.01 0.01	Dilutive impact of share-based payments <sup>i</sup>		853		455		601
Diluted EPS, GAAP\$ 0.53\$ (0.06)\$ 0.13Non-GAAP adjustments - pretax:Restructuring costse0.030.020.02Legal settlements and feesd0.01—0.02Rebranding impairments and accelerated amortizatione—0.02—Applicant tracking system costsf0.010.010.02	Adjusted weighted average common shares - diluted, non-GAAP		37,034		36,328		36,778
Non-GAAP adjustments - pretax:Restructuring costs $^{c}$ 0.030.020.02Legal settlements and fees $^{d}$ 0.01—0.02Rebranding impairments and accelerated amortization $^{c}$ —0.02—Applicant tracking system costs $^{f}$ 0.010.010.02	Reconciliation:						
Non-GAAP adjustments - pretax:Restructuring costs $^{c}$ 0.030.020.02Legal settlements and fees $^{d}$ 0.01—0.02Rebranding impairments and accelerated amortization $^{c}$ —0.02—Applicant tracking system costs $^{f}$ 0.010.010.02	Diluted EPS, GAAP	\$	0.53	\$	(0.06)	\$	0.13
Legal settlements and feesd $0.01$ — $0.02$ Rebranding impairments and accelerated amortizatione— $0.02$ —Applicant tracking system costsf $0.01$ $0.01$ $0.02$							
Rebranding impairments and accelerated amortization <sup>e</sup> $-$ 0.02 $-$ Applicant tracking system costs <sup>f</sup> 0.01 0.01 0.02	Restructuring costs <sup>c</sup>		0.03		0.02		0.02
Applicant tracking system costs <sup>f</sup> 0.01 0.01 0.02	Legal settlements and fees <sup>d</sup>		0.01		_		0.02
			_		0.02		_
Adjusted EPS, non-GAAP <sup>h</sup> \$ 0.58 \$ (0.01) \$ 0.19			0.01		0.01		0.02
	Adjusted EPS, non-GAAPh	\$	0.58	\$	(0.01)	\$	0.19

#### Cross Country Healthcare, Inc. Consolidated Balance Sheets (Unaudited, amounts in thousands)

	March 31, 2021	December 31, 2020		
Assets				
Current assets:				
Cash and cash equivalents	\$ 13,488	\$ 1,600		
Accounts receivable, net	245,489	170,003		
Prepaid expenses	5,430	5,455		
Insurance recovery receivable	4,752	4,698		
Other current assets	575	1,355		
Total current assets	269,734	183,111		
Property and equipment, net	13,026	12,351		
Operating lease right-of-use assets	9,835	10,447		
Goodwill	90,924	90,924		
Trade names, indefinite-lived	5,900	5,900		
Other intangible assets, net	33,341	34,831		
Other non-current assets	19,593	19,409		
Total assets	\$ 442,353	\$ 356,973		
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable and accrued expenses	\$ 59,797	\$ 49,877		
Accrued employee compensation and benefits	53,383	35,540		
Operating lease liabilities - current	4,803	4,509		
Other current liabilities	3,677	3,497		
Total current liabilities	121,660	93,423		
Revolving credit facility	96,025	53,408		
Operating lease liabilities - non-current	13,978	15,234		
Non-current deferred tax liabilities	6,858	6,592		
Long-term accrued claims	24,624	25,412		
Other long-term liabilities	5,534	7,995		
Total liabilities	268,679	202,064		
Commitments and contingencies				
Stockholders' equity:				
Common stock	4	4		
Additional paid-in capital	309,711	310,388		
Accumulated other comprehensive loss	(1,286)	(1,280)		
Accumulated deficit	(135,289)	(154,737)		
Total Cross Country Healthcare, Inc. stockholders' equity	173,140	154,375		
Noncontrolling interest in subsidiary	534	534		
Total stockholders' equity	173,674	154,909		
Total liabilities and stockholders' equity	\$ 442,353	\$ 356,973		

#### Cross Country Healthcare, Inc. Segment Data<sup>j</sup> (Unaudited, amounts in thousands)

				T	hree Months	Ended				Year-over- Year	Sequential
	N	March 31,	% of	l	March 31,	% of	De	cember 31,	% of	% change	% change
		2021	Total		2020	Total		2020	Total	Fav (Unfav)	Fav (Unfav)
Revenue from services:											
Nurse and Allied Staffing	\$	313,008	95 %	\$	191,883	91 %	\$	199,177	92 %	63 %	57 %
Physician Staffing		16,233	5 %		18,181	9 %		16,429	8 %	(11)%	(1)%
	\$	329,241	100 %	\$	210,064	100 %	\$	215,606	100 %	57 %	53 %
Contribution income: <sup>k</sup>	' <u>-</u>										
Nurse and Allied Staffing	\$	37,417		\$	13,822		\$	22,835		171 %	64 %
Physician Staffing		1,428			631			942		126 %	52 %
		38,845			14,453			23,777		169 %	63 %
Corporate overhead <sup>1</sup>		14,211			11,270			14,907		(26)%	5 %
Depreciation and amortization		2,253			3,296			2,199		32 %	(2)%
Acquisition and integration-related costs <sup>b</sup>		_			77			_		100 %	— %
Restructuring costs <sup>c</sup>		1,238			564			842		(120)%	(47)%
Impairment charges <sup>e</sup>		149			_			166		(100)%	10 %
Income (loss) from operations	\$	20,994		\$	(754)		\$	5,663		NM	271 %

NM-Not meaningful

### Cross Country Healthcare, Inc. Summary Condensed Consolidated Statements of Cash Flows (Unaudited, amounts in thousands)

	Three Months Ended								
	March 31,		M	arch 31,	Dec	ember 31,			
		2021		2020		2020			
Net cash (used in) provided by operating activities	\$	(24,927)	\$	17,162	\$	1,929			
	Ф	. , ,	Ф	,	Ф	•			
Net cash used in investing activities		(1,186)		(962)		(956)			
Net cash provided by (used in) financing activities		38,004		(4,599)		(2,827)			
Effect of exchange rate changes on cash		(3)		(34)		8			
Change in cash and cash equivalents		11,888		11,567		(1,846)			
Cash and cash equivalents at beginning of period		1,600		1,032		3,446			
Cash and cash equivalents at end of period	\$	13,488	\$	12,599	\$	1,600			

## Cross Country Healthcare, Inc. Other Financial Data (Unaudited)

		Three Months Ended					
		March 31,		March 31,	Dec	cember 31,	
	2021		2020		2020		
Consolidated gross profit margin <sup>m</sup>		21.7 %		23.6 %		25.2 %	
Nurse and Allied Staffing statistical data:							
FTEs <sup>n</sup>		6,614		7,145		5,798	
Average Nurse and Allied Staffing revenue per FTE per day <sup>o</sup>	\$	522	\$	290	\$	368	
Physician Staffing statistical data:							
Days filled <sup>p</sup>		9,469		10,199		9,911	
Revenue per day filled <sup>q</sup>	\$	1,714	\$	1,783	\$	1,658	

- (a) Adjusted EBITDA, a non-GAAP financial measure, is defined as net (loss) income attributable to common shareholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on sale of business, other expense (income), net, equity compensation, applicant tracking system costs, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.
- (b) Acquisition and integration-related costs include costs for valuation adjustments related to the contingent consideration liability for the Mediscan acquisition.
- (c) Restructuring costs are primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.
- (d) Legal settlements and fees include legal settlement charges as presented on the consolidated statements of operations as well as legal fees pertaining to non-operational legal matters which are included in selling, general and administrative expenses. For the three months ended March 31, 2021 and December 30, 2020, we incurred legal fees related to various legal matters outside the normal course of operations.
- (e) Impairment charges of \$0.1 million for the three months ended March 31, 2021 related to the write-off of a discontinued software development project. Impairment charges of \$0.2 million for the three months ended December 31, 2020 related to right-of-use assets and related property and

- equipment in connection with leases that were vacated during the second and third quarters of 2020. Rebranding impairments and accelerated amortization related to finite-lived trade names in connection with the rebranding initiatives.
- (f) Applicant tracking system costs are related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling, general and administrative expenses on the consolidated statement of operations and included in corporate overhead in segment data.
- (g) Cross Country Talent Acquisition Group, LLC was controlled by the Company but not wholly owned. The Company recorded the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. Effective December 31, 2020, the sole professional staffing services agreement held by this joint venture was terminated. The Company subsequently entered into a direct staffing agreement with the hospital system.
- (h) Adjusted EPS, a non-GAAP financial measure, is defined as net (loss) income attributable to common shareholders per diluted share before the diluted EPS impact of acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, rebranding impairments and accelerated amortization, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system costs, and nonrecurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company.
- (i) Due to the net loss for the three months ended March 31, 2020, 455 shares (in thousands) were excluded from diluted weighted average shares.
- (j) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. In the first quarter of 2021, the Company modified its reportable segments and disclosed two reportable segments Nurse and Allied Staffing and Physician Staffing beginning in the first quarter of 2021. Revenue in the amount of \$2.8 million and \$3.6 million, and contribution income of \$0.6 million and contribution loss of \$0.3 million, included in the previously-reported Search segment have been reclassified to Nurse and Allied Staffing for the three months ended December 31, 2020 and March 31, 2020, respectively.
- (k) Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.
- (l) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).
- (m) Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.
- (n) FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.
- (o) Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.
- (p) Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.
- (q) Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

Cross Country Healthcare, Inc.
William J. Burns, Executive Vice President & Chief Financial Officer
561-237-2555
wburns@crosscountry.com

Source: Cross Country Healthcare, Inc.